Ivermectin in the treatment of COVID-19-friend or foe?

dc.contributor.authorSchellack, Natalie
dc.contributor.authorPadayachee, N.
dc.contributor.authorSchellac, G.
dc.contributor.emailnatalie.schellack@up.ac.zaen_US
dc.date.accessioned2022-10-12T10:19:22Z
dc.date.available2022-10-12T10:19:22Z
dc.date.issued2021-03-10
dc.description.abstractThe global number of deaths due to COVID-19 is almost at the two million mark, with over 35 000 deaths in South Africa. Although there are hopes of a safe and effective vaccination programme, the increasing number of COVID-19 cases in the country is putting a significant strain on the healthcare system. Ivermectin, an antiparasitic drug, has been widely published on social media platforms and news outlets as a socalled miracle drug for the treatment of COVID-19. Ivermectin is not registered in SA as a drug for human use, but rather as a veterinary and agricultural product. Currently, from a small number of randomised controlled trials (RCTs), there does seem to be a signal of evidence for the use of ivermectin in the management of COVID-19. Pharmacists must, however, remain cognisant of their ethical responsibilities as well as the applicable regulations that prohibit the procurement and dispensing of any unregistered medicine.en_US
dc.description.departmentPharmacologyen_US
dc.description.urihttps://medpharm.co.za/about-our-journals/sagpen_US
dc.identifier.citationSchellack, N., Padayachee, N., Schellac, G. 2021, 'Ivermectin in the treatment of COVID-19— friend or foe?', South African General Practitioner, vol. 88, no. 1, pp. 11-14.en_US
dc.identifier.issn2706-9613 (print)
dc.identifier.issn2706-9621 (online)
dc.identifier.urihttps://repository.up.ac.za/handle/2263/87647
dc.language.isoenen_US
dc.publisherMedpharm publicationsen_US
dc.rights© 2021 The Author(s). Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0].en_US
dc.subjectAvermectinen_US
dc.subjectIvermectinen_US
dc.subjectMacrocyclic lactoneen_US
dc.subjectEndectocideen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.titleIvermectin in the treatment of COVID-19-friend or foe?en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Schellack_Ivermectin_2021.pdf
Size:
89.12 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: